Nontraumatic Stupor and Coma without MCC DRG Reimbursement

Summary & Overview

Nontraumatic Stupor and Coma without MCC: Inpatient Reimbursement Overview

DRG 081 addresses hospital stays for nontraumatic stupor and coma without Major Complication or Comorbidity, focusing on acute altered consciousness requiring evaluation and monitoring. Precise documentation and coding influence inpatient reimbursement because Diagnosis-Related Group assignment determines Medicare payment levels tied to clinical severity and resource use.

Nontraumatic Stupor and ComaDRG Nontraumatic Stupor and Coma without MCCDRG 081Diagnosis-Related GroupInpatient ReimbursementMedicareNeurologyCritical CareAcute CareHospital Coding

DRG 081 Overview

DRG 081 covers inpatient admissions for nontraumatic stupor and coma without Major Complication or Comorbidity and encompasses acute alterations in consciousness not caused by external injury. These cases often require neurologic evaluation, critical care monitoring, and diagnostics to determine etiology such as metabolic, toxicologic, infectious, or neurologic causes. This Diagnosis-Related Group matters for Medicare payment because it groups resource use for medically complex, high-acuity hospital stays that do not meet higher-severity payment tiers. Accurate coding of diagnoses and accompanying comorbid conditions determines assignment to this Diagnosis-Related Group and associated reimbursement.

National Payment Rates

Across commercial payers the observed rate range runs from a low of $7.4K (BCBS median) up to a high of $25K (Cigna max), with a widest spread of about $18K between payer extremes. Refer to the table and chart below for payer-specific percentiles and distribution details. Payer-level variation is notable among Aetna, Anthem, Cigna, and BCBS.

Mean Rates by Payer — National — DRG 081

The CMS 2023 data represent national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($9.4k), average submitted covered charges ($45.4k), average Medicare payment amount ($7.1k), and total discharges (688).

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska’s DRG 081 mean payments vary notably across payers, with Anthem and Blue Cross Blue Shield clustered at 14K and Cigna markedly higher with a 22K mean (range in the appendix spans roughly 12K–36K). This state distribution shows a clear deviation from many national median levels, driven primarily by Cigna’s elevated mean. See the table and chart below for payer-level detail.

Key Insights for Alaska

Cigna is the highest paying payer in Alaska with a mean of 22K, while Anthem and Blue Cross Blue Shield are the lowest, each reporting a mean of 14K.
The Alaska market shows a notable spread (12K–36K observed in the appendix) driven by Cigna’s higher mean; overall means for Anthem/Blue Cross Blue Shield (14K) sit above some national payer medians but below Cigna’s state mean.

Clinical Trials

Acute neuroprotective and resuscitation intervention trials: studies focusing on rapid interventions administered in the emergency department or ICU to improve neurologic recovery in adults presenting with nontraumatic stupor or coma, often stratified by etiology (e.g., metabolic, toxicologic, hypoxic-ischemic, infectious). These trials evaluate timing, dosing, and combinations of supportive protocols (airway management, targeted temperature strategies, seizure suppression, and hemodynamic optimization) to reduce secondary brain injury. Results inform in-hospital care pathways, resource allocation for critical care services, and short-term reimbursement drivers such as ICU length of stay and use of advanced monitoring.
Comparative effectiveness and diagnostic strategy studies: research comparing approaches to rapid etiologic diagnosis and their impact on outcomes, such as protocolized use of advanced imaging, EEG monitoring, biomarkers, and standardized metabolic/toxicology testing versus usual care. These studies enroll heterogeneous inpatient populations with unexplained depressed consciousness to determine which diagnostic bundles most efficiently identify treatable causes and reduce unnecessary testing. Findings are relevant to providers and payers by identifying high-value diagnostic algorithms that can shorten time-to-treatment, lower costs from avoidable tests, and reduce complications from delayed diagnosis.
Post-acute outcomes, rehabilitation, and disposition studies: longitudinal research following survivors of nontraumatic stupor or coma through hospital discharge, rehabilitation, and up to one year to characterize functional recovery, cognitive outcomes, readmission drivers, and long-term care needs. These cohort and intervention studies evaluate predictors of discharge disposition, effectiveness of early mobility and cognitive rehabilitation programs, and transitional care models that may reduce readmissions and long-term institutionalization. Evidence guides discharge planning, rehabilitation resource utilization, and payer decisions about coverage for post-acute services that can improve functional outcomes and downstream costs.

Related Codes

089-CONCUSSION-WITH-CC

Concussion with Complication or Comorbidity: Inpatient Reimbursement Overview

057-DEGENERATIVE-NERVOUS-SYSTEM-DISORDERS-WITHOUT-MCC

Degenerative Nervous System Disorders without MCC: Inpatient Reimbursement Overview

026-CRANIOTOMY-AND-ENDOVASCULAR-INTRACRANIAL-PROCEDURES-WITH-CC

Craniotomy and Endovascular Intracranial Procedures with CC: Inpatient Reimbursement Overview

073-CRANIAL-AND-PERIPHERAL-NERVE-DISORDERS-WITH-MCC

Cranial and Peripheral Nerve Disorders with MCC: Inpatient Reimbursement Overview

029-SPINAL-PROCEDURES-WITH-CC-OR-SPINAL-NEUROSTIMULATORS

Spinal Procedures with CC or Spinal Neurostimulators: Inpatient Reimbursement Overview

021-INTRACRANIAL-VASCULAR-PROCEDURES-WITH-PRINCIPAL-DIAGNOSIS-HEMORRHAGE-WITH-CC

Intracranial Vascular Procedures with Principal Diagnosis Hemorrhage with CC: Inpatient Reimbursement Overview

102-HEADACHES-WITH-MCC

Headaches with Major Complication or Comorbidity: Inpatient Reimbursement Overview

075-VIRAL-MENINGITIS-WITH-CC-MCC

Viral Meningitis with CC/MCC: Inpatient Reimbursement Overview

054-NERVOUS-SYSTEM-NEOPLASMS-WITH-MCC

Nervous System Neoplasms with MCC: Inpatient Reimbursement Overview

023-CRANIOTOMY-WITH-MAJOR-DEVICE-IMPLANT-OR-ACUTE-COMPLEX-CNS-PRINCIPAL-DIAGNOSIS-WITH-MCC-OR-ANTINEOPLASTIC-IMPLANT-OR-EPILEPSY-WITH-NEUROSTIMULATOR

Craniotomy with Major Device Implant or Complex CNS DRG 023: Inpatient Reimbursement Overview

Showing 1–10 of 71

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

OpenPayer

Summary & Overview

Nontraumatic Stupor and Coma without MCC: Inpatient Reimbursement Overview

DRG 081 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes